|Bid||136.46 x 100|
|Ask||138.83 x 200|
|Day's Range||138.15 - 138.65|
|52 Week Range||114.07 - 139.37|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.06%|
Hopes for Trump's tax reforms, abating North Korea fears, lower-than-expected damage from Hurricane Irma and record stock market highs rekindled the love for U.S. equity ETFs last week.
Acadia Pharmaceuticals' (ACAD) commercial teams have been carrying out promotional efforts to create awareness for Nuplazid among physicians with the intent to have them prescribe the drug.
The odds may be better for small-cap managers, but they're still long.